Oseltamivir
- Generic Name
- Oseltamivir
- Brand Names
- Ebilfumin, Tamiflu
- Drug Type
- Small Molecule
- Chemical Formula
- C16H28N2O4
- CAS Number
- 196618-13-0
- Unique Ingredient Identifier
- 20O93L6F9H
- Background
Oseltamivir (marketed as the product TamifluⓇ), is an antiviral neuraminidase inhibitor used for the treatment and prophylaxis of infection with influenza viruses A (including pandemic H1N1) and B. Oseltamivir exerts its antiviral activity by inhibiting the activity of the viral neuraminidase enzyme found on the surface of the virus, which prevents budding f...
- Indication
According to FDA prescribing information, oseltamivir is indicated for the treatment of acute, uncomplicated illness due to influenza A and B infection in patients 2 weeks of age and older who have been symptomatic for no more than 48 hours . In particular, this agent is indicated in adults and children including full-term neonates who present with symptoms ...
- Associated Conditions
- Flu caused by Influenza, Influenza A Virus Infection, Influenza A, Influenza B, Influenza Type B
- Associated Therapies
- -
Administration of Allogenic UC-MSCs as Adjuvant Therapy for Critically-Ill COVID-19 Patients
- Conditions
- Interventions
- First Posted Date
- 2020-07-07
- Last Posted Date
- 2020-07-07
- Lead Sponsor
- Indonesia University
- Target Recruit Count
- 40
- Registration Number
- NCT04457609
- Locations
- 🇮🇩
Sulianti Saroso Center for Infectious Disease, Jakarta, DKI Jakarta, Indonesia
🇮🇩Universitas Indonesia Hospital, Depok, West Java, Indonesia
🇮🇩Persahabatan General Hospital, Jakarta, DKI Jakarta, Indonesia
Randomised Evaluation of COVID-19 Therapy
- Conditions
- Interventions
- Drug: Lopinavir-RitonavirBiological: Convalescent plasmaBiological: ImmunoglobulinDrug: CorticosteroidDrug: Synthetic neutralising antibodiesDrug: EmpagliflozinDrug: AnakinraDrug: High Dose CorticosteroidDrug: SotrovimabDrug: PaxlovidDrug: Baloxavir MarboxilDrug: HydroxychloroquineDrug: AzithromycinDrug: TocilizumabDrug: AspirinDrug: Dimethyl fumarateDrug: ColchicineDrug: BaricitinibDrug: OseltamivirDrug: Molnupiravir
- First Posted Date
- 2020-05-11
- Last Posted Date
- 2024-01-05
- Lead Sponsor
- University of Oxford
- Target Recruit Count
- 70000
- Registration Number
- NCT04381936
- Locations
- 🇻🇳
Oxford University Clinical Research Unit, Centre for Tropical Medicine, Ho Chi Minh City, Vietnam
🇬🇭Kumasi Center for Collaborative Research in Tropical Medicine KNUST, Kumasi, Ghana
🇮🇳Indian Council of Medical Research, Division of Epidemiology and Communicable Diseases, New Delhi, India
Safety and Effectiveness of Mesenchymal Stem Cells in the Treatment of Pneumonia of Coronavirus Disease 2019
- Conditions
- Interventions
- First Posted Date
- 2020-05-01
- Last Posted Date
- 2020-05-01
- Lead Sponsor
- Fuzhou General Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT04371601
- Locations
- 🇨🇳
Fuzhou General Hospital, Fuzhou, Fujian, China
Hydroxychloroquine, Oseltamivir and Azithromycin for the Treatment of COVID-19 Infection: An RCT
- Conditions
- Interventions
- First Posted Date
- 2020-04-08
- Last Posted Date
- 2022-02-10
- Lead Sponsor
- Shehnoor Azhar
- Target Recruit Count
- 550
- Registration Number
- NCT04338698
- Locations
- 🇵🇰
Gujranwala Medical College, Gujrānwāla, Pakistan
🇵🇰Khyber Teaching Hospital, Peshawar, Pakistan
🇵🇰Akram Medical Complex, Lahore, Pakistan
A Randomized,Open,Controlled Clinical Study to Evaluate the Efficacy of ASC09F and Ritonavir for 2019-nCoV Pneumonia
- Conditions
- Interventions
- First Posted Date
- 2020-02-07
- Last Posted Date
- 2020-03-17
- Lead Sponsor
- Tongji Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT04261270
- Locations
- 🇨🇳
Department and Institute of Infectious Disease, Wuhan, Hubei, China
A Prospective/Retrospective,Randomized Controlled Clinical Study of Antiviral Therapy in the 2019-nCoV Pneumonia
- Conditions
- Interventions
- First Posted Date
- 2020-02-05
- Last Posted Date
- 2020-03-17
- Lead Sponsor
- Tongji Hospital
- Target Recruit Count
- 400
- Registration Number
- NCT04255017
- Locations
- 🇨🇳
Department and Institute of Infectious Disease, Wuhan, Hubei, China
Evaluation of the Safety and Efficacy of a Monoclonal Antibody to Treat Influenza
- First Posted Date
- 2019-04-04
- Last Posted Date
- 2020-01-18
- Lead Sponsor
- MedImmune LLC
- Registration Number
- NCT03903718
Adjunctive Sirolimus and Oseltamivir Versus Oseltamivir Alone for Treatment of Influenza
- First Posted Date
- 2019-04-03
- Last Posted Date
- 2023-11-27
- Lead Sponsor
- Chinese University of Hong Kong
- Target Recruit Count
- 160
- Registration Number
- NCT03901001
- Locations
- 🇭🇰
Prince of Wales Hospital, Hong Kong, Hong Kong
Oseltamivir Versus Paracetamol for Influenza-like Illness During the Influenza Season
- First Posted Date
- 2018-11-27
- Last Posted Date
- 2019-01-30
- Lead Sponsor
- Rambam Health Care Campus
- Target Recruit Count
- 436
- Registration Number
- NCT03754686
Study to Assess the Safety, Pharmacokinetics, and Efficacy of Baloxavir Marboxil in Healthy Pediatric Participants With Influenza-Like Symptoms
- First Posted Date
- 2018-08-14
- Last Posted Date
- 2020-04-29
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 173
- Registration Number
- NCT03629184
- Locations
- 🇺🇸
The Probe Medical Research, Los Angeles, California, United States
🇺🇸Kentucky Pediatric Research Center, Bardstown, Kentucky, United States
🇺🇸Orange County Research Institute, Ontario, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.